Spire Wealth Management Raises Position in Edwards Lifesciences Corporation $EW

Spire Wealth Management grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1,477.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 46,997 shares of the medical research company’s stock after purchasing an additional 44,017 shares during the quarter. Spire Wealth Management’s holdings in Edwards Lifesciences were worth $3,676,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Arkadios Wealth Advisors purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $300,000. Daymark Wealth Partners LLC raised its position in shares of Edwards Lifesciences by 1.9% in the 2nd quarter. Daymark Wealth Partners LLC now owns 8,328 shares of the medical research company’s stock worth $651,000 after buying an additional 157 shares during the period. Econ Financial Services Corp purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth $889,000. Quaker Wealth Management LLC raised its position in shares of Edwards Lifesciences by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 611 shares of the medical research company’s stock worth $48,000 after buying an additional 1,222 shares during the period. Finally, Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 15.7% in the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after buying an additional 1,584,958 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 1.0%

NYSE:EW opened at $83.53 on Friday. The business’s 50-day moving average is $77.57 and its two-hundred day moving average is $76.79. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $84.66. The firm has a market capitalization of $49.04 billion, a PE ratio of 12.02, a price-to-earnings-growth ratio of 3.97 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company posted $0.67 earnings per share. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several research reports. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Robert W. Baird increased their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Wells Fargo & Company increased their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Finally, Oppenheimer lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.89.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.